Evolving Needs and a Treatment Option for R/R Multiple Myeloma

For oncology teams considering treatment options in relapsed/refractory multiple myeloma, what distinguishes ZENBEXUS (iberdomide), and what does the evidence show for its use in combination?

In this session, Daniel Gutkin, PharmD, MS, Oncology Medical Science Liaison at Bristol Myers Squibb, will examine:

• How ZENBEXUS works compared with earlier immunomodulatory drugs
• Efficacy findings for ZENBEXUS with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd)
• Safety findings from EXCALIBER-RRMM and the ZENBEXUS prescribing information

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.